Boao Lecheng Approves Use of Sanofi’s Tzield as First-Line Therapy for Type 1 Diabetes Delay
Tzield (teplizumab), recognized as the world’s first and only targeted therapy for delaying the onset...
Huadong Medicine’s ROR1-Targeting ADC HDM2005 Receives FDA Clinical Trial Approval
Huadong Medicine Co., Ltd (SHE: 000963), a pharmaceutical company based in China, has announced that...
Moon Biotech Secures Exclusive State-Owned Fund Investment in Series C+ Round
Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly...
China’s CDE Launches Pilot Program for Electronic Drug Registration Filings
The National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) in China has issued...
China’s Sichuan Huiyu Pharmaceutical Halts Generic Cytosar Launch Following Strategy Review
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a pharmaceutical company based in China, has announced...
China’s Henlius Biotech Partners with Sermonix for Japan Development of Breast Cancer Drug
Shanghai Henlius Biotech Inc. (HKG: 2696), a prominent biopharmaceutical company based in China, has announced...
MicroPort Endovascular to Fully Acquire Optimum Medical Device in $65M Deal
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading Chinese medical technology company, has...
Supercede Therapeutics Partners with Shanghai Universities for Anti-Tumor Cachexia Drug Developmen
Fudan University and East China Normal University (ECNU) have entered into a global rights cooperation...
Eisai and Biogen Launch Alzheimer’s Drug Leqembi in China Following Market Approval
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, in partnership with Biogen Inc. (NASDAQ:...
Healthcare Firms Line Up for HKEX IPOs as Biotech Market Recovery Gains Momentum
A number of healthcare companies are seeking to capitalize on the recovering market conditions by...
Hinova Pharmaceuticals’ HP518 Earns FDA Fast-Track Designation for AR+ Triple Negative Breast Cancer
Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, has announced that it has...
Jiangsu Hengrui’s Henagliflozin Gains Expanded Indication for Type 2 Diabetes Treatment in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Gloria Bio’s Motixafortide Approved as Urgently Needed Import Drug by Hainan Medical Products Administration
Guangzhou Gloria Biosciences Co., Ltd, a biopharmaceutical company based in China, has received approval from...
Winning Health Partners with Unicom Digitization Medical to Boost Medical Industry Innovation
Winning Health (SHE: 300253), a Shanghai-based company in the medical information industry, has entered into...
BeiGene’s Tislelizumab Approved by China’s NMPA for First-Line Extensive Stage Small Cell Lung Cancer
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a biopharmaceutical company, has announced that its programmed-death...
Hisense Medical Teams Up with Tianjin Government and Yujin AI for Intelligent Medical R&D
Hisense Medical Equipment Co., Ltd, a leading medical equipment provider based in China, has entered...
Staidson Pharmaceutical’s Bemiltenase Alfa Earns Orphan Drug Designation from US FDA for Hemophilia Treatment
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced...
Cigna & CMB Life Insurance Partners with Cleveland Clinic Foundation to Enhance Medical Diagnosis for Chinese Patients
Cigna & CMB Life Insurance Co., a joint venture between Cigna Corporation, a U.S.-based global...
Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
IASO Biotherapeutics’ RD118 CAR-T Therapy Receives Clinical Trial Approval for Multiple Myeloma
IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit...